There’s no question that Bristol-Myers Squibb Co.’s lead in the PD-1 race is being chipped away by Merck & Co. Inc., but the blow will be softened by a $625m payment to Bristol and global PD-1 partner Ono Pharmaceutical Co. Ltd. as well as ongoing royalties from Merck’s Keytruda sales.
Patent Settlement Offers Some Salve For Bristol’s PD-1 Wounds
Bristol-Myers Squibb has taken a beating over setbacks for its Opdivo and its immuno-oncology portfolio, but a settlement reached with Merck over Keytruda’s patent infringement is a momentary victory for the PD-1 pioneer.
